Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,551 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Degenerative Conditions, Neurologic Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Exercise and Cognitive Training on Cognitive Function in Older Adults

NCT01038726
View directory record Official record
Conditions
Aging, Alzheimer's Disease
Interventions
Exercise Training, Cognitive Training, Flexibility Training, Educational Sessions
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 4 Interventional

Treatment of Behavioral Symptoms in Alzheimer's Disease

NCT00009217
View directory record Official record
Conditions
Alzheimer's Disease, Psychosis, Agitation
Interventions
Haloperidol-Haloperidol, Haloperidol-Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 4 Interventional Results available

Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training

NCT00120874
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Individualized management of AD including caregiver training, Memantine
Behavioral · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease

NCT05424276
View directory record Official record
Conditions
Parkinson Disease
Interventions
IkT-148009 (risvodetinib), Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
28
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Reseda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Not applicable Interventional

Anticholinergic Therapy for Overactive Bladder in Parkinson's Disease

NCT00892450
View directory record Official record
Conditions
Parkinson's Disease, Overactive Bladder
Interventions
Oxybutynin and darifenacin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 10, 2026, 6:38 PM EDT
Completed No phase listed Observational

Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome

NCT02854917
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nilotinib in Cognitively Impaired Parkinson Disease Patients 001

NCT02281474
View directory record Official record
Conditions
Parkinson's Disease, Parkinson's Disease Dementia, Diffuse Lewy Body Disease
Interventions
Nilotinib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 10, 2026, 6:38 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PET Tau - Neurodegenerative Disease Imaging

NCT03143374
View directory record Official record
Conditions
Neurodegenerative Disease
Interventions
18F-AV-1451
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 10, 2026, 6:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

NCT07287397
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma

NCT02839720
View directory record Official record
Conditions
Cutaneous Neurofibroma, Neurofibromatosis Type 1, Optic Nerve Glioma
Interventions
Laboratory Biomarker Analysis, Selumetinib Sulfate
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional

Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia

NCT02640729
View directory record Official record
Conditions
Lewy Body Dementia, Visual Hallucinations
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Fountain Valley, California • Boca Raton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of Bryostatin in Moderately Severe to Severe Alzheimer's Disease Subjects Not On Memantine

NCT03560245
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Bryostatin, Placebo
Drug · Other
Lead sponsor
Neurotrope Bioscience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Fresno, California • Los Alamitos, California • Santa Ana, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2020 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism

NCT02231073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Exercise and Education for Parkinson's Disease
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 4 Interventional Results available

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2013 · Synced Oct 10, 2026, 6:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

5-HT RBD REM Sleep Behavior Disorder

NCT06467461
View directory record Official record
Conditions
Dementia With Lewy Bodies, Parkinson Disease, REM Sleep Behavior Disorder
Interventions
Skin biopsy, Speech testing, Ultra high field 7T MRI
Diagnostic Test
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional Results available

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT02292186
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Caregiver Stress: Interventions to Promote Health and Wellbeing

NCT01188070
View directory record Official record
Conditions
Health Promotion
Interventions
Usual Care, Psycho-education, Psycho-education plus physical exercise
Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 10, 2026, 6:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease

NCT04799470
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Novel DBS stimulation patterns
Device
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 10, 2026, 6:38 PM EDT
Recruiting Not applicable Interventional

Tongue-strengthening Exercises in People With ALS.

NCT07295990
View directory record Official record
Conditions
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
Interventions
Isometric Lingual Strength Exercises
Procedure
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 10, 2026, 6:38 PM EDT
Terminated Phase 2Phase 3 Interventional

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

NCT05116813
View directory record Official record
Conditions
Parkinson Disease, Dyskinesia, Drug-Induced, Dyskinesias
Interventions
Dipraglurant
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Augusta, Georgia • Kansas City, Kansas • New Brunswick, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 10, 2026, 6:38 PM EDT
Completed Phase 2 Interventional

Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy

NCT00481013
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Valproic Acid (VPA), Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 10, 2026, 6:38 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel

NCT01891383
View directory record Official record
Conditions
Dementia, Traumatic Brain Injury (TBI), Mild Cognitive Impairment (MCI), Chronic Traumatic Encephalopathy (CTE), Post-traumatic Stress Disorder (PTSD)
Interventions
Not listed
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
50 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Yountville, California • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 10, 2026, 6:38 PM EDT
Withdrawn Phase 2 Interventional

Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome

NCT01475383
View directory record Official record
Conditions
Tourette's Syndrome
Interventions
PF-03654746, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Oct 10, 2026, 6:38 PM EDT